化学位移MRI监测肝细胞癌化疗栓塞递送:初步临床转化的多中心可行性研究
这项前瞻性多中心可行性研究纳入28例接受传统经导管动脉化疗栓塞的肝细胞癌患者,用化学位移脂肪-水MRI评估碘化油在肿瘤内的递送。24小时肿瘤内碘化油滞留率为46%(12/26个肿瘤),1个月时为47%(18/38个肿瘤);化学位移MRI测量的肿瘤碘化油体积在EASL定义的非缓解者中显著更高(P=0.02),提示其可能用于按EASL标准进行肿瘤缓解分层。
要点
- 化学位移MRI可在传统经导管动脉化疗栓塞后1个月内评估肿瘤内碘化油递送。
- 化学位移MRI测量的肿瘤碘化油体积在EASL定义的非缓解者中显著更高(P=0.02)。
- CT测量的肿瘤体积在EASL缓解者与非缓解者间无显著差异(P=0.06)。
核心结论
- 化学位移MRI可在肝细胞癌患者传统经导管动脉化疗栓塞后1个月内评估肿瘤内碘化油递送,肿瘤碘化油体积可能是按EASL标准进行肿瘤缓解分层的潜在工具。
研究设计与样本
- 前瞻性、机构审查委员会批准、符合《健康保险携带与责任法案》的研究,纳入28例接受传统经导管动脉化疗栓塞的肝细胞癌患者(平均年龄66岁±8[SD],22例男性),在1个月随访时行化学位移MRI。
- 以改良实体瘤疗效评价标准与欧洲肝病研究学会(EASL)标准评估缓解者与非缓解者,按病灶比较肿瘤大小(MRI与CT)、CT衰减与强化、脂肪含量百分比及肿瘤:正常组织比值(MRI)。
- 不良事件与总生存期(Kaplan-Meier法)为次要终点;临床试验注册号NCT02173119。
关键影像表现/征象
- 传统经导管动脉化疗栓塞后24小时局灶性肿瘤碘化油滞留率为46%(12/26个肿瘤),1个月时为47%(18/38个肿瘤)。
诊断标准与关键数值
- 以改良实体瘤疗效评价标准与EASL标准定义缓解者与非缓解者;化学位移MRI测量的肿瘤碘化油体积在EASL定义的非缓解者中统计学显著更高(P=0.02)。
- CT测量的肿瘤体积在EASL定义缓解者与非缓解者间无显著差异(P=0.06)。
- 多柔比星剂量(P=0.53)、局灶性脂肪存在(P=0.83)及局灶性脂肪合并低多柔比星剂量复合终点(P=0.97)均不能对传统经导管动脉化疗栓塞后的总生存期进行分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To demonstrate the feasibility of using chemical shift fat-water MRI methods to visualize and measure intrahepatic delivery of ethiodized oil to liver tumors following conventional transarterial chemoembolization (cTACE). Materials and Methods Twenty-eight participants (mean age, 66 years ± 8 [SD]; 22 men) with hepatocellular carcinoma (HCC) treated with cTACE were evaluated with follow-up chemical shift MRI in this Health Insurance Portability and Accountability Act-compliant prospective, institutional review board-approved study. Uptake of ethiodized oil was evaluated at 1-month follow-up chemical shift MRI. Measurements of tumor size (MRI and CT), attenuation and enhancement (CT), fat content percentage, and tumor:normal ratio (MRI) were compared by lesion for responders versus nonresponders, as assessed with modified Response Evaluation Criteria in Solid Tumors and European Association for the Study of the Liver (EASL) criteria. Adverse events and overall survival by the Kaplan-Meier method were secondary end points. Results Focal tumor ethiodized oil retention was 46% (12 of 26 tumors) at 24 hours and 47% (18 of 38 tumors) at 1 month after cTACE. Tumor volume at CT did not differ between EASL-defined responders and nonresponders (P = .06). Tumor ethiodized oil volume measured with chemical shift MRI was statistically significantly higher for EASL-defined nonresponders (P = .02). Doxorubicin dosing (P = .53), presence of focal fat (P = .83), and a combined end point of focal fat and low doxorubicin dosing (P = .97) did not stratify overall survival after cTACE. Conclusion Chemical shift MRI allowed for assessment of tumor delivery of ethiodized oil out to 1 month after cTACE in participants with HCC and demonstrated tumor ethiodized oil volume as a potential tool for stratification of tumor response by EASL criteria. Keywords: MRI, Chemical Shift Imaging, CT, Hepatic Chemoembolization, Ethiodized Oil Clinicaltrials.gov registration no.: NCT02173119 Supplemental material is available for this article. © RSNA, 2023.
引用
- Gordon AC, Lewandowski RJ, Li W, et al. Chemical Shift MRI Monitoring of Chemoembolization Delivery for Hepatocellular Carcinoma: Multicenter Feasibility of Initial Clinical Translation. Radiol Imaging Cancer. 2023. PMID: 37233207. doi:10.1148/rycan.220019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。